<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689416</url>
  </required_header>
  <id_info>
    <org_study_id>D4411M00010</org_study_id>
    <nct_id>NCT00689416</nct_id>
  </id_info>
  <brief_title>Effects of Crestor on Inflammation of Atherosclerotic Plaques</brief_title>
  <official_title>Exploratory Study of New Imaging Biomarkers for Measurement of Carotid Plaque Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to investigate the effect of 40 mg dose of rosuvastatin on
      carotid plaque inflammation measured with MRI and PET scanning, to evaluate whether these
      techniques are promising for future proof of principle studies. A number of patients will
      receive placebo as a control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison between the active and the placebo group regarding changes in MRI contrast enhancement in terms of the transfer constant (Ktrans) for the carotid region</measure>
    <time_frame>MRI scan at enrolment visit and within group after 3 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between the active and the placebo group regarding changes in MRI contrast enhancement measured as fractional plasma volume (Vp) and changes in 18FDG uptake in terms of standardised uptake value (SUV), respectively</measure>
    <time_frame>MRI scan at enrolment visit and within group after 3 months. 18FDG at randomisation visit (baseline) and within group after 3 months treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in carotid MRI contrast enhancement in terms of Ktrans and Vp.</measure>
    <time_frame>At enrolment visit and within group after 3 months treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 18FDG uptake in terms of SUV.</measure>
    <time_frame>At randomisation visit (baseline) and within group after 3 months treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Inflammatory Activity in Carotid Arteries</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>40 mg, tablet, once daily for 3 months.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>40 mg, tablet, once daily for 3 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a non-calcified plaque of at least 2 mm over an at least 6 mm length on
             first MR scan with an uptake of contrast agent on the dynamic MRI scan

          -  Signed written Informed Consent.

          -  Healthy men 18 - 70 years, women 60 - 70

        Exclusion Criteria:

          -  Use of a statin within six months before randomization.

          -  Use of lipid altering medication other than statins within the last six months.

          -  Clinical evidence of metabolic or vascular disease requiring statin or other lipid
             lowering pharmacological or non-pharmacological treatment.

          -  Total cholesterol &gt; 8, LDL-C &gt; 6 or TG &gt; 6 mmol/L at enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Håkan Ahlström, MD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Leonsson-Zachrissson, MD, Study Physician</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D Mölndal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>June 29, 2009</last_update_submitted>
  <last_update_submitted_qc>June 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Björn Carlsson, MD, PhD, Medical Science Director, Discovery Medicine CDT</name_title>
    <organization>AstraZeneca R&amp;D Mölndal, Sweden</organization>
  </responsible_party>
  <keyword>imaging biomarkers</keyword>
  <keyword>MRI</keyword>
  <keyword>FDG-PET/CT scanning</keyword>
  <keyword>Crestor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

